Oil prices rebound sharply on smaller-than-feared OPEC+ output hike
PRINCETON, N.J. - Bristol Myers Squibb (NYSE:BMY), a prominent pharmaceutical company with $47.7 billion in annual revenue and currently trading near its 52-week low, announced it will provide significant discounts to eligible cash-paying patients for two of its medications starting in 2026. According to InvestingPro analysis, the company appears undervalued based on its Fair Value estimates. The company will offer Eliquis at more than 40% below current list price and Sotyktu at more than 80% below current list price through its direct-to-patient platform.
Beginning January 2026, Sotyktu, a treatment for moderate-to-severe plaque psoriasis, will be available through the new BMS Patient Connect platform. This follows the recent launch of a similar program for Eliquis, an anticoagulant medication, earlier this month through the Bristol Myers Squibb-Pfizer Alliance.
The BMS Patient Connect platform will allow eligible cash-paying U.S. patients with prescriptions to purchase these medications with shipping available across all 50 states and Puerto Rico. The company stated the platform is designed to provide transparency into medication costs and simplify access.
"We are taking a leading role in removing barriers, providing transparency and lowering out-of-pocket costs so patients in the United States can get the treatments they need," said Christopher Boerner, board chair and CEO of Bristol Myers Squibb, in a press release statement.
Sotyktu is an oral prescription medication used to treat moderate-to-severe plaque psoriasis in adults who may benefit from systemic therapy or phototherapy. It is the first tyrosine kinase 2 inhibitor approved worldwide.
Eliquis is prescribed to reduce stroke risk in patients with atrial fibrillation, treat blood clots, and prevent blood clots after hip or knee replacement surgery.
The company indicated that BMS Patient Connect will also provide patient support resources and may include additional Bristol Myers Squibb medicines appropriate for this model in the future. With a robust dividend yield of 5.62% and strong free cash flow generation, BMY maintains a "GOOD" financial health rating according to InvestingPro. Subscribers can access 12 additional ProTips and comprehensive analysis in the Pro Research Report, offering deeper insights into BMY’s financial outlook and market position.
In other recent news, Bristol Myers Squibb announced promising results from its Phase 3 EXCALIBER-RRMM study. The trial, which evaluated iberdomide combined with daratumumab and dexamethasone, showed a statistically significant improvement in minimal residual disease negativity rates for patients with relapsed or refractory multiple myeloma. The study will continue to assess additional endpoints such as progression-free survival and overall survival. Additionally, Bristol Myers Squibb plans to launch its schizophrenia treatment, Cobenfy, in the United Kingdom in 2026, pricing it similarly to its U.S. list price of $22,500 annually. The company has also amended its partnership with BioNTech for the investigational bispecific antibody BNT327, agreeing to a $1.5 billion upfront payment and potential additional milestone payments. In related developments, Veeva Systems received a reaffirmed Buy rating from Stifel, with Bristol Myers Squibb committing to Veeva’s Vault CRM platform. These developments highlight significant strategic initiatives and partnerships for Bristol Myers Squibb.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.